Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

BACKGROUND AND AIMS: The UNIFI long-term extension [LTE] study reports the efficacy and safety of subcutaneous 90 mg ustekinumab through 3 years of maintenance therapy. METHODS: Patients randomised to ustekinumab every 12 weeks [q12w] or every 8 weeks [q8w] at maintenance baseline [N = 348] and rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Abreu, Maria T, Rowbotham, David S, Danese, Silvio, Sandborn, William J, Miao, Ye, Zhang, Hongyan, Tikhonov, Ilia, Panaccione, Remo, Hisamatsu, Tadakazu, Scherl, Ellen J, Leong, Rupert W, Arasaradnam, Ramesh P, Afif, Waqqas, Peyrin-Biroulet, Laurent, Sands, Bruce E, Marano, Colleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426670/
https://www.ncbi.nlm.nih.gov/pubmed/35239968
http://dx.doi.org/10.1093/ecco-jcc/jjac030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426670/
https://www.ncbi.nlm.nih.gov/pubmed/35239968
http://dx.doi.org/10.1093/ecco-jcc/jjac030

Ejemplares similares